SGLT2 inhibitors were associated with a lower risk of serious adverse events (RR 0.90, 95% CI 0.86 to 0.94, <i>P</i> < 0.001), death (RR 0.78, 95% CI 0.64 to 0.94, <i>P</i> < 0.05), gastroenteritis (RR 0.38, 95% CI 0.20 to 0.72, <i>P</i> < 0.05), arthralgia (RR 0.72, 95% CI 0.54 to 0.96, <i>P</i> < 0.05), hypertension (RR 0.61, 95% CI 0.50 to 0.75, <i>P</i> < 0.001), and edema/peripheral edema (RR 0.49, 95% CI 0.33 to 0.72, <i>P</i> < 0.001) compared to placebo. Here, SLC5A2 is linked to hypertensive disorder.